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seemed reduced, especially the gastrointestinal form. Palifermin
was generally well tolerated and safe.
ANC>0.5109/l PLT>20109/l
Palifermin group
median (d) 16.7 16.6
range 9-42 8-45
Control group
median (d) 16.7 17.6
range 8-34 7-54
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ADV is a serious cause of morbidity and mortality in patients
undergoing alloSCT. ADV infection rates are 4-6% in adults
and as high as 47% in children following alloSCT (Hoffman et
al BBMT 2001). The reported mortality rate for disseminated
ADV ranges from 8-54 % with higher rates reported in patients
with ADV pneumonia (73%) and disseminated disease (61%)
(Ljungman, Eur J Clin Microbiol & Infect Dis, 2004). We
sought to determine the incidence, demographics, site of dis-
ease, treatment course, and outcome of ADV infection in chil-
dren and adolescents following alloSCT from 1/1/2000-12/31/
04. Eighty three children and adolescents underwent 91
alloSCT. Median age 6.5 (0.5 – 21.75) years, sex: M/F (52/39).
AlloSCT donors included: Matched Family Donor (MFD),
Bone Marrow (BM)/Peripheral Blood (PB) – 34 (37.4%), Un-
related Cord Blood(UCB) – 51 (56%), Related Cord Blood-
(RCB) - 3 (3.3%), Matched Unrelated Donor(MUD) – 3 (3.3%).
Conditioning: 36 (40%) ablative conditioning, 55 (60%) re-
duced intensity conditioning. The majority (90%) received
Mycophenolate Mofetil/Tacrolimus GVHD prophylaxis (Os-
unkwo/Cairo et al, BBMT 2004). Recipients at risk for CMV
received Foscarnet/Ganciclovir prophylaxis (Shereck/Cairo et al
PBC 2006). ADV swabs and tissue biopsies samples cultured in
remel microtest viral media. Ten (11%) systemic and/or inva-
sive ADV infections were identiﬁed. Underlying diagnosis: 5
malignant (1ALL, 1 AML, 1 NHL, 2 NBL), 5 non-malignant
(1WAS, 4 SAA). Donor source: 4 UCB, 1 MUD, 2 MFDPB, 1
MFDBM, 2 MFDBM  PB. Sites of ADV  culture: Gastro-
enteritis (GE) – 4, GE/Pneumonitis – 3, GE/Nasopharyngeal –
2, Cystits – 1. Treatment (Tx): cidofovir (CDV) (1mg/kg TIW)
[n8], observation [n1], ADV found on post-mortem culture
[n1]. Outcome: 8 expired (6 non-ADV infection, 1 GVHD, 1
CNS hemorrhage); 2 survivors (1 post tx with no evidence of
ADV, 1 ADV  no tx.) There were no ADV related deaths for
0% mortality. Adenovirus infection is an important contributor
to post alloSCT morbidity and mortality. In patients trans-
planted at our center from 1/2000 –12/31/04 there was an 11 %
incidence of adenovirus infection. Tx with CDV improves the
outcome of patients with ADV infection in the post-transplant
period. More rapid diagnosis with PCR-based technology will
allow earlier diagnosis of systemic disease in alloSCT recipients
resulting in prompt therapeutic intervention which may lead to
improved outcomes.
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Introduction: Thrombotic complications are not uncommon
pre or post hematopoietic stem cell transplant (HSCT). However,
little is known about the etiology, frequency of inherited disorders
associated with thrombosis (factor V Leiden, Prothrombin variant
or MTHFR polymorphisms) treatment and outcome of these pa-
tients with thrombotic events during autologous or allogeneic
HSCT. METHODS: We have retrospectively evaluated 65
HSCT patients (n 42 autologus and n 13 allogeneic), for the
presence of thrombotic complications from the start of condition-
ing therapy until 100 days post HSCT from July 1998 to July 2006.
A total of 65 patients presented with a thrombotic event during the
investigational period. Most thrombotic episodes occurred within
the ﬁrst 4 weeks of admission. All patients were evaluated with
either venous Doppler or echocardiographic testing prior to initi-
ation of therapy. All patients were treated with low-molecular-
weight-heparin according to a in-house protocol as previous pub-
lished (Bone Marrow transplantation 2005: 35(11):1071-7.)
Molecular assays were performed for the following hypercoaguable
conditions: MTHFR C677T, homocysteine levels, Factor V-lei-
den deﬁciency, AT-III, Protein C & S and sticky platelet syn-
drome. Results For the entire group 97% of the cohort had a
molecular defect: 47% were MTHFR C677T either homozygous
or heterozygous gene polymorphisms, Factor V leiden 13% and
hyperhomocysteine in 47% (mean homocysteine level 15.5 ) and
53% had sticky platelet syndrome. Conclusion: Our data suggest
that HSCT patients who develop a thrombotic event during the
ﬁrst 100 days of transplantation should be evaluated for, hyperco-
aguable states by conventional methods using molecular anaylsis.
Also, this group of patients is at high risk for the complications of
DVT and should be treated with conventional anticoagulation
when feasible.
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Background: RIC regimens can be used to extend transplanta-
tion to elderly or debilitated patients, not normally considered for
stem cell transplants (SCT). Cardiac complications have been re-
ported in patients undergoing fully myleoablative HSCT. How-
ever, in patients undergoing RIC the incidence, predisposing risk
factors, and outcome in patients who develop cardiac complica-
tions is unknown. METHODS: We retrospectively reviewed the
outcome of patients who suffered a cardiac complication during the
time period from July 2000 until July 2006. During that time
period 97 HSCT encompassed a RIC regimen. A total of 13
patients during the investigational period sustained a cardiac event.
Most events occurred within the pre and peri-transplant period. All
patients were evaluated by laboratory evaluation, cardiology and
echocardiographic testing. Results: All patients underwent condi-
tioning with Busulfan 3mg/kg, ﬂudarabine 25mg/m2 and TBI
followed by allogeneic HSCT from a related HLA-matched donor
(n4) or a matched unrelated donor (n9) stem cell source was
peripheral blood (n13). GVHD prophylaxis was tacrolimus and
mycophenolate (MMF) (n13). Median age was 55 years (range
42-66), median day onset was 3 (range day -3 to 9), arrhythmias:
Atrial ﬁbrillation (n7), Atrial ﬂutter (n5) Supraventricular
tachycardia (n1). Troponin was elevated in 6/13 (46%) of pa-
tients, median BNP was 679 (range 488-989), electrolyte abnor-
malities occurred in (n8/13) patients. Hemodynamic compro-
mise occurred in 7/13 (53%) of patients, 5/13 (38%) required
intubation and mechanical ventilation. Median time to medical
conversion was 2 days no mechanical cardio version was required.
Relapse occurred in 4/13 (30%) of patients after discharge. Pre-
disposing risk factors for cardiac complications in our group con-
sisted of 4/13 having a pre-existing cardiac condition, 69% (9/13)
had received anthracycline based therapy in the past. Conclusion:
The incidence of a cardiac complication in the study group at our
center was 13% (13/97), a prior history of a cardiac event or
exposure to anthracycline based therapy was a signiﬁcant risk factor
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